Articles & Video
Commercialization of Cell & Gene Therapies
This ebook presents insights from industry leaders, including partnering strategies, process technologies and control considerations.
REPORT: COVID-19 Response in Cell & Gene Therapy Manufacturing 2021
This exclusive report uncovers the major changes in the cell and gene therapy sector during the COVID-19 pandemic.
Allogeneic and Autologous Cell Therapies Survey 2021
What pitfalls come with each product type in cell therapy manufacturing and how can they be alleviated? We want to hear from you!
COVID hit cell and gene therapy trials and suppliers but experts see signs of recovery
COVID-19 disrupted cell and gene therapy trials as well as the contractors and suppliers that support them, according to experts.
Cell & Gene Therapy Manufacturing & Commercialization US Post Event Report
We pick the top moments from the event in its first hybrid format.
COVID-19 has benefited investment in the cell and gene therapy sector, say 78% of industry professionals
We investigate how the COVID-19 pandemic has transformed business, finance and investment in cell and gene therapies.
Life Sciences Survey: COVID-19 Impacts One Year On
Take part in our industry survey on the impacts of COVID-19 on the life sciences one year on to get exclusive early access to the final report.
63% of cell and gene therapy professionals changed their supply chain strategies due to COVID-19
We examine new data on the challenges in cell and gene therapy supply chain and manufacturing as a result of the COVID-19 pandemic.
Personalized Medicine: Neoantigen Cancer Vaccines and T Cell Therapy
We look at precision antigen selection carried out with a personalized immune response profiling platform, demonstrated at TIDES: Oligonucleotide and Peptide Therapeutics.
REPORT: Diversity, Equity and Inclusion in the Life Sciences 2021
Explore the Diversity, Equity and Inclusion in the Life Sciences 2021 report based on an exclusive study of 483 industry professionals.
Advancing Gene Therapies: Evaluating Immunogenicity and its Impact on Therapeutic Potential
What are the considerations for selecting the best immunogenicity assay?
Survey: Cell & Gene Therapy COVID-19 Response
What changes are happening in the cell and gene therapy sector as a result of the pandemic? Tell us your experience.
SURVEY: Diversity, Equity and Inclusion in the Life Sciences 2021
Complete our survey on Diversity, Equity and Inclusion in the Life Sciences 2021 to get exclusive early access to the final report.
Post-event Report: Cell & Gene Therapy Bioprocessing & Commercialization 2020
We review the key highlights from the virtual conference, including analysis of the hottest sessions by BioProcess International magazine.
Pharma’s role in maintaining cancer mortality progress during COVID-19
COVID-19 is threatening the progress made in reducing cancer mortality. Pharma has a pivotal role to play in helping patients and providers navigate the new reality of cancer treatment during the pandemic, and beyond.
BioProcess International Fall Digital Week 2020
We explore the agenda for the upcoming BioProcess International Fall Digital Week 2020.
BioProcess International 2020 Post-Event Report
Explore the highlights of the BioProcess International 2020 virtual conference in the post-event round-up.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
Ebook: The Future of the Cell and Gene Therapy Industry
What can we expect next from the cell and gene therapy sector? This ebook explores the potential paths ahead, from optimized CAR-T to automated bioprocessing.
When to outsource manufacturing? Advice for cell and gene therapy developers
What scenarios could determine when is best to outsource manufacturing of cell and gene therapies to a CDMO?